Berkeley Capital Partners LLC Purchases Shares of 8,507 Becton, Dickinson and Company $BDX

Berkeley Capital Partners LLC purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, Holdings Channel reports. The firm purchased 8,507 shares of the medical instruments supplier’s stock, valued at approximately $1,592,000.

Other institutional investors have also recently modified their holdings of the company. SOA Wealth Advisors LLC. grew its holdings in Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares during the last quarter. Activest Wealth Management lifted its position in shares of Becton, Dickinson and Company by 285.3% in the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares in the last quarter. Bell Investment Advisors Inc boosted its stake in shares of Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 128 shares during the last quarter. Cornerstone Planning Group LLC increased its position in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares in the last quarter. Finally, Grey Fox Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company in the 3rd quarter valued at about $32,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 3,416 shares of company stock valued at $675,557 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $182.29 on Friday. The business’s fifty day moving average price is $197.64 and its 200 day moving average price is $192.19. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $185.02. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $51.91 billion, a P/E ratio of 29.74, a PEG ratio of 13.24 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the business posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase program on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be issued a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. Becton, Dickinson and Company’s dividend payout ratio is currently 68.52%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BDX shares. Royal Bank Of Canada set a $172.00 price target on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Citigroup decreased their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Morgan Stanley boosted their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company lowered their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.